Elisabeth Maillart
Overview
Explore the profile of Elisabeth Maillart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
134
Citations
1426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thouvenot E, Laplaud D, Lebrun-Frenay C, Derache N, Le Page E, Maillart E, et al.
JAMA
. 2025 Mar;
PMID: 40063041
Importance: Vitamin D deficiency is a risk factor for multiple sclerosis (MS) and is associated with the risk of disease activity, but data on the benefits of supplementation are conflicting....
2.
De Seze J, Labauge P, Liblau R, Martinez M, Moreau T, Suchet L, et al.
Adv Ther
. 2025 Feb;
PMID: 39969782
Introduction: Dimethyl fumarate (DMF) has demonstrated a favorable benefit-risk profile in patients with relapsing-remitting multiple sclerosis (RRMS). Some patients may develop lymphopenia on DMF; therefore, LymphoTEC evaluated absolute lymphocyte count...
3.
Marignier R, Villacieros-Alvarez J, Espejo C, Arrambide G, Fissolo N, Gutierrez L, et al.
J Neurol Neurosurg Psychiatry
. 2025 Feb;
PMID: 39939136
Background: Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) have emerged as important biomarkers in multiple sclerosis (MS) and aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD)....
4.
Mainguy M, Casey R, Vukusic S, Lebrun-Frenay C, Berger E, Kerbrat A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Feb;
12(2):e200371.
PMID: 39933125
Background And Objectives: Older studies reported an increased risk of relapse after in vitro fertilization (IVF) in women with multiple sclerosis (MS), which has not been confirmed by more recent...
5.
Maillart E, Dubessy A, Shor N, Piljan M, Decombe R, Lubetzki C, et al.
Neurology
. 2025 Feb;
104(5):e213399.
PMID: 39913883
Objectives: Several treatments have been approved for the prevention of attacks in AQP4-IgG+ neuromyelitis optica spectrum disorder (NMOSD). However, because of the rarity of the disease, little is known concerning...
6.
Gougeon M, Seffer V, Hoxha C, Maillart E, Popoff M
Toxins (Basel)
. 2025 Jan;
17(1).
PMID: 39852980
Multiple sclerosis (MS) is a chronic immune-mediated neurological disorder, characterized by progressive demyelination and neuronal cell loss in the central nervous system. Many possible causes of MS have been proposed,...
7.
Ramdani R, Pique J, Deschamps R, Ciron J, Maillart E, Audoin B, et al.
Mult Scler
. 2025 Jan;
13524585241311435.
PMID: 39812323
Background: The clinical course of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is variable. However, robust markers of poor outcome and/or relapse risk are still missing. Objective: To evaluate the...
8.
Villacieros-Alvarez J, Espejo C, Arrambide G, Dinoto A, Mulero P, Rubio-Flores L, et al.
Neurol Neuroimmunol Neuroinflamm
. 2025 Jan;
12(2):e200362.
PMID: 39752619
Objectives: To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods: This...
9.
Androdias G, Lunemann J, Maillart E, Amato M, Audoin B, Bruijstens A, et al.
Brain
. 2024 Dec;
PMID: 39707906
The development of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has been highly successful in recent decades. It is now widely accepted that early initiation of DMTs...
10.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, et al.
J Neurol Neurosurg Psychiatry
. 2024 Dec;
PMID: 39643429
Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains...